IS4871A - Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) - Google Patents

Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)

Info

Publication number
IS4871A
IS4871A IS4871A IS4871A IS4871A IS 4871 A IS4871 A IS 4871A IS 4871 A IS4871 A IS 4871A IS 4871 A IS4871 A IS 4871A IS 4871 A IS4871 A IS 4871A
Authority
IS
Iceland
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
established
Prior art date
Application number
IS4871A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4871A publication Critical patent/IS4871A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS4871A 1996-05-03 1998-10-16 Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) IS4871A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number Publication Date
IS4871A true IS4871A (is) 1998-10-16

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4871A IS4871A (is) 1996-05-03 1998-10-16 Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)

Country Status (42)

Country Link
US (2) US6211222B1 (is)
EP (1) EP0912521B1 (is)
JP (1) JP3148254B2 (is)
KR (1) KR100339935B1 (is)
CN (2) CN1112359C (is)
AP (4) AP1147A (is)
AR (1) AR006906A1 (is)
AT (1) ATE292626T1 (is)
AU (1) AU725576B2 (is)
BG (1) BG64211B1 (is)
BR (1) BR9709051A (is)
CA (2) CA2252982C (is)
CO (1) CO4650038A1 (is)
CZ (1) CZ292825B6 (is)
DE (1) DE69732966T2 (is)
DZ (1) DZ2217A1 (is)
EA (1) EA002272B1 (is)
ES (1) ES2238079T3 (is)
GT (1) GT199700043A (is)
HK (1) HK1019443A1 (is)
HN (1) HN1997000046A (is)
HR (1) HRP970227B1 (is)
HU (1) HUP9902459A3 (is)
ID (1) ID16856A (is)
IL (2) IL126547A (is)
IS (1) IS4871A (is)
MA (1) MA24158A1 (is)
MY (1) MY132499A (is)
NO (1) NO312959B1 (is)
NZ (1) NZ332240A (is)
OA (1) OA10904A (is)
PE (1) PE64598A1 (is)
PL (1) PL329836A1 (is)
SK (1) SK148298A3 (is)
TN (1) TNSN97070A1 (is)
TR (1) TR199802202T2 (is)
TW (1) TW449585B (is)
UA (1) UA65536C2 (is)
UY (1) UY24532A1 (is)
WO (1) WO1997042174A1 (is)
YU (1) YU16397A (is)
ZA (1) ZA973804B (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
DK0983249T3 (da) * 1997-05-08 2002-07-08 Pfizer Prod Inc Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
SK6252000A3 (en) * 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
HUP0100330A3 (en) * 1997-11-04 2002-03-28 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
WO2003051344A1 (en) 2001-12-14 2003-06-26 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation_using a non-polypeptide camp level modulator
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US8277809B2 (en) * 2006-04-21 2012-10-02 Centocor, Inc. CXCL13 antagonists and their use for the treatment of inflammatory diseases
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (is) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
PT630367E (pt) * 1992-03-09 2000-10-31 Zeneca Ltd Novos arilindazoles e sua utilizacao como herbicidas
SK279958B6 (sk) * 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
AU702105B2 (en) * 1994-10-20 1999-02-11 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
CA2203181C (en) * 1994-10-21 2001-08-07 Robert L. Heimann Corrosion preventing buffer system for metal products
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
DK0983249T3 (da) * 1997-05-08 2002-07-08 Pfizer Prod Inc Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater

Also Published As

Publication number Publication date
BG102946A (en) 1999-11-30
EA199800882A1 (ru) 1999-06-24
EP0912521B1 (en) 2005-04-06
GT199700043A (es) 1998-10-02
JP3148254B2 (ja) 2001-03-19
US6127398A (en) 2000-10-03
DE69732966T2 (de) 2005-09-08
ID16856A (id) 1997-11-13
CA2252982A1 (en) 1997-11-13
SK148298A3 (en) 2000-02-14
AP1146A (en) 2003-02-25
IL152083A0 (en) 2003-05-29
BR9709051A (pt) 1999-08-03
PL329836A1 (en) 1999-04-12
EP0912521A1 (en) 1999-05-06
AP1147A (en) 2003-02-25
HK1019443A1 (en) 2000-02-11
HUP9902459A2 (hu) 1999-11-29
NO312959B1 (no) 2002-07-22
CZ349298A3 (cs) 1999-09-15
AP0102304A0 (en) 1997-11-03
IL126547A0 (en) 1999-08-17
NO985095L (no) 1998-12-29
TNSN97070A1 (fr) 2005-03-15
JPH11508284A (ja) 1999-07-21
AP2001002294A0 (en) 2001-12-31
CZ292825B6 (cs) 2003-12-17
AU725576B2 (en) 2000-10-12
UA65536C2 (en) 2004-04-15
AU1937397A (en) 1997-11-26
MA24158A1 (fr) 1997-12-31
YU16397A (sh) 1999-12-27
US6211222B1 (en) 2001-04-03
EA002272B1 (ru) 2002-02-28
ATE292626T1 (de) 2005-04-15
CA2389918A1 (en) 1997-11-13
KR100339935B1 (ko) 2002-07-18
DE69732966D1 (de) 2005-05-12
HUP9902459A3 (en) 2001-10-29
ZA973804B (en) 1998-11-02
WO1997042174A1 (en) 1997-11-13
AP2001002304A0 (en) 2001-12-31
NO985095D0 (no) 1998-11-02
NZ332240A (en) 2000-07-28
TW449585B (en) 2001-08-11
CO4650038A1 (es) 1998-09-03
ES2238079T3 (es) 2005-08-16
MY132499A (en) 2007-10-31
HRP970227B1 (en) 2002-06-30
HN1997000046A (es) 1997-06-26
UY24532A1 (es) 2000-09-29
HRP970227A2 (en) 2000-12-31
IL126547A (en) 2003-03-12
BG64211B1 (bg) 2004-05-31
KR20000010751A (ko) 2000-02-25
CA2252982C (en) 2002-10-08
CN1112359C (zh) 2003-06-25
AP9700975A0 (en) 1997-07-31
CN1217714A (zh) 1999-05-26
DZ2217A1 (fr) 2002-12-03
OA10904A (en) 2001-10-11
PE64598A1 (es) 1998-10-26
AR006906A1 (es) 1999-09-29
CN1422849A (zh) 2003-06-11
TR199802202T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
IS4871A (is) Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)
IS4979A (is) Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)
IS4910A (is) Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata
AU2396897A (en) 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
IL154016A0 (en) Pyrazole derivatives and their use as protein kinase inhibitors
AU5704594A (en) Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
HUP0102113A1 (hu) 2-(2,6-Dioxo-piperidin-3-il)-izoindolinszármazékok, előállításuk és alkalmazásuk, mint a gyulladáskeltő citokinek inhibitorai
EP0987263A3 (en) Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
SI1480983T1 (sl) Heteroarilno substituirani 2-piridinil in 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-onski derivati
NO20015062L (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
AU2955195A (en) Tumor necrosis factor receptor-ii-associated protein kinase and methods for its use
PL365824A1 (en) Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders
HK1066804A1 (en) Derivatives of indole and their use as phosphodiesterase 4 inhibitors
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
ZA905593B (en) Tumor necrosis factor(tnf)inhibitor and method for obtaining the same